Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)

NCT03845296 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT03845296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03845296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2
Overall status
Completed
Start date
April 16, 2019
Completion date
September 21, 2024
Enrollment
64 (actual)
Sites
950

Conditions

As the registry lists them; a condition with its own page is linked.

deleterious brca1 gene mutation, deleterious brca2 gene mutation, loss of heterozygosity, lung non-small cell squamous carcinoma, recurrent large cell lung carcinoma, recurrent lung adenocarcinoma, recurrent lung non-small cell carcinoma, recurrent non-squamous non-small cell lung carcinoma, stage iv lung cancer ajcc v8, stage iva lung cancer ajcc v8, stage ivb lung cancer ajcc v8